MDXG
MIMEDX GROUP, INC.
NASDAQ · Healthcare · Biotechnology · US
$3.20
−1.54%Year over year
Reported trailing growth
- Revenue
- -22.8%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- -67.7%
- Operating cash flow
- -69.4%
Forward estimates
Based on analyst estimates
- Revenue
- -6.1%
- EBITDA
- +209.5%
- EPS
- +151.0%
Three-year CAGR
- Revenue
- +16.1%
- EBITDA
- +43.1%
- EBIT
- +31.2%
- Net income
- -15.1%
- EPS
- -17.1%
- Free cash flow
- +71.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026